Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MARKSANS

MARKSANS

HealthcarePharmaceuticals & Biotechnology₹13384 cr market cap
₹299.05 ▲ +1.54% today As of 19 Nov 2026
52-week low ₹156.8952-week high ₹347.60

-15.3% from the 52-week high · +87.7% above the low

Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 1,412 full-time employees. The company went IPO on 2002-04-03. The firm operates through the manufacture of pharmaceutical formulation segment. The firm is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. The company marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The firm has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. The company also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The firm has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.

The short version. MARKSANS reported revenue of ₹940 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹141 crore (up 43.9% year on year). Return on equity was 13.8% in Mar 2026. Promoter holding was 43.87% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

MARKSANS trades 15.3% below its 52-week high and 87.7% above its 52-week low.

Change over period: —

1M-2.8%
3M-9.9%
6M+35.5%
1Y+53.1%

2 · The business

Is it growing?

Sales, year on year+30.6%

Sep 2026 revenue of ₹940 cr.

Profit, year on year+43.9%

Sep 2026 net profit of ₹141 cr.

Net margin15.0%

1.4 pts higher than a year earlier.

3-year growth16.4% profit

Revenue compounded at 16.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue94084185675472062071682
Net profit14115714811398589105
Net margin %15.018.717.315.013.69.412.815.3
EPS (₹)3.123.473.272.52.171.290.22.31

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2951262217718521491137611341000
Net profit4183831426518723912176
Net margin %14.214.614.414.312.517.310.67.6
EPS (₹)9.220.846.935.854.565.832.951.86

3 · The quality

How well does it turn capital into profit?

Return on equity was 13.8% in Mar 2026; debt to equity is 0.01.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %13.815.515.215.2
Return on capital %17.518.719.018.8
EBITDA margin %22.522.222.920.9
Net margin %13.814.214.113.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR16.6%17.0%
Profit CAGR16.4%11.9%
Debt to equity0.01
Interest cover24.2x
Current ratio5.17
P/E ratio24.0

4 · The owners

Who holds it, and are they adding?

Promoter holding43.87%

Unchanged over 8 quarters.

Foreign institutions19.06%

Down 2.9 pts over 8 quarters.

Domestic institutions5.54%

Up 1.24 pts over 8 quarters.

Mutual fund schemes31

+8 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter43.8743.8743.8743.8743.8743.8743.8743.870.0
FII21.9622.219.8816.928.1216.7617.4719.06-2.9
DII4.34.565.55.285.916.576.195.54+1.24
Public29.8729.3730.7533.9342.0932.7932.4731.53+1.66

Mutual fund holdings · Oct 2026

31 schemes hold this stock

23 the month before.

  • Kotak MNC Fund2.91% of NAV
  • Kotak Special Opportunities Fund2.6% of NAV
  • Kotak Healthcare Fund2.22% of NAV
  • UTI - Healthcare Fund2.14% of NAV
  • Unifi Flexi Cap Fund2.06% of NAV
  • UTI Small Cap Fund1.92% of NAV
  • SAMCO ACTIVE MOMENTUM FUND1.75% of NAV
  • Old Bridge Flexi Cap Fund1.57% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MARKSANS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MARKSANS

What is the MARKSANS share price?

MARKSANS (MARKSANS) last closed at ₹299.05, up 1.54% on the day. Its 52-week range is ₹156.89 to ₹347.60.

What is the market cap of MARKSANS?

MARKSANS has a market capitalisation of about ₹13,384 crore. Its price-to-earnings ratio is 24.0.

How are MARKSANS's latest results?

MARKSANS reported revenue of ₹940 crore for Sep 2026, up 30.6% from a year earlier. Net profit was ₹141 crore (up 43.9% year on year). Return on equity was 13.8% in Mar 2026. Promoter holding was 43.87% in Sep 2026, up 0.00 points over 8 quarters.

Who owns MARKSANS?

As of Sep 2026, shareholding was: Promoter 43.87%, FII 19.06%, DII 5.54%, Public 31.53%.

How many mutual funds hold MARKSANS?

31 mutual fund schemes held MARKSANS in October 2026. That compares with 23 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 01 Aug 2025 · Final Dividend - Rs. 0.8
  • 17 Sep 2024 · Final Dividend - Rs. 0.6
  • 07 Jun 2023 · Final Dividend - Rs. 0.5
  • 19 Aug 2022 · Final Dividend - Rs. 0.25
  • 15 Sep 2021 · Final Dividend - Rs. 0.25
  • 22 Sep 2020 · Final Dividend - Rs. 0.1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.